Risk Factors for Post-ERCP Pancreatitis in High-Risk Patients Receiving Post-procedure Rectal Indomethacin

被引:12
|
作者
Kang, Xiaoyu [1 ]
Zheng, Liyue [1 ]
Zeng, Wei [2 ,3 ]
Yang, Shengye [1 ]
Sun, Hao [4 ]
Zhang, Rongchun [1 ]
Wang, Xiangping [1 ]
Wang, Biaoluo [1 ]
Tao, Qin [1 ]
Yao, Shaowei [1 ]
Chen, Jie [1 ]
Pan, Yanglin [1 ]
Guo, Xuegang [1 ]
机构
[1] Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China
[2] Chinese PLA 174 Hosp, Dept Gastroenterol, Xiamen, Fujian, Peoples R China
[3] Xiamen Univ, Chenggong Hosp, Dept Gastroenterol, Xiamen, Fujian, Peoples R China
[4] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
ERCP; Post-ERCP pancreatitis; Indomethacin; Risk factors; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; STENT PLACEMENT; CANNULATION; COMPLICATIONS; METAANALYSIS; PREVENTION; REDUCE; MANAGEMENT; EFFICACY;
D O I
10.1007/s11605-018-3864-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Post-ERCP pancreatitis (PEP) is the most common adverse event of ERCP. Rectal indomethacin has been widely administered to decrease the incidence of PEP in high-risk patients. However, it cannot completely prevent the occurrence of PEP. The purpose of the study was to evaluate the risk factors for PEP in high-risk patients receiving post-ERCP indomethacin. Methods From June 2012 to July 2015, patients undergoing ERCP and at high risk for PEP in three tertiary hospitals in China were enrolled. All patients received indomethacin after the procedure. Patient-related and procedure-related risk factors for PEP were collected. Logistic regression analysis was used to investigate the risk factors. Results Seven hundred ninety patients at high risk for PEP received post-ERCP indomethacin. The incidence of overall PEP and moderate-to-severe PEP was 8.0 and 1.5%, respectively. In multivariate analysis, suspected sphincter of Oddi dysfunction (SOD) (OR 2.73; 95%CI 1.38-5.43; p=0.004), the presence of hilar obstruction (OR 4.53; 95%CI 1.60-12.81; p=0.004), number of cannulation attempts 13 (OR 2.00; 95%CI 1.07-3.77; p=0.030), inadvertent pancreatic duct (PD) cannulation 1 (OR 2.26; 95%CI 1.04-4.90; p=0.040), and pancreatic contrast injections 1 (OR 2.30; 95%CI 1.02-5.23; p=0.046) were high risk factors for overall PEP. For moderate-to-severe PEP, suspected SOD (OR 4.67; 1.19-18.35; p=0.027), the presence of hilar obstruction (OR 7.95; 1.39-44.97; p=0.010), and more cannulation attempts (OR 3.71; 1.09-12.65; p=0.036) were three independent risk factors. Conclusions A substantial number of high-risk patients had PEP even receiving post-ERCP rectal indomethacin. The independent risk factors included suspected SOD, hilar stricture, more cannulation attempts, inadvertent PD cannulation, and PD contrast injections.
引用
收藏
页码:1903 / 1910
页数:8
相关论文
共 50 条
  • [21] Outcome and Risk Factors for Post-ERCP Pancreatitis
    Kim, Youn Joo
    Lee, Sang Hyub
    Yang, Ki Young
    Seo, Jeong Kyun
    GASTROINTESTINAL ENDOSCOPY, 2009, 69 (05) : AB233 - AB234
  • [22] Outcomes and Risk Factors for Post-ERCP Pancreatitis
    Kim, Y. J.
    Kim, Y. T.
    Park, J. K.
    Park, S. C.
    Lee, S. H.
    PANCREAS, 2009, 38 (08) : 1015 - 1016
  • [23] Somatostatin administration prior to ERCP is effective in reducing the risk of post-ERCP pancreatitis in high-risk patients
    Zhao, Li-Na
    Yu, Tao
    Li, Chu-Qiang
    Lai, Yu
    Chen, Qi-Kui
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 8 (02) : 509 - 514
  • [24] Rectal Indomethacin to Prevent Post-ERCP Pancreatitis REPLY
    Elmunzer, B. Joseph
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (03): : 278 - 279
  • [25] EFFICACY OF RECTAL INDOMETHACIN IN PREVENTION OF POST-ERCP PANCREATITIS
    Fatima, Hina
    Hussain, Mudassar
    Akhtar, Ziyad Humayun
    Raja, Ikram Ul Haq
    Ali, Bushra
    Nawaz, Arif Amir
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 5 (11): : 12068 - 12073
  • [26] Rectal Indomethacin to Prevent Post-ERCP Pancreatitis Reply
    Levenick, John M.
    GASTROENTEROLOGY, 2016, 151 (03) : 569 - 570
  • [27] A Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin Alone for the Prevention of Post-ERCP Pancreatitis in High Risk Patients
    Kamal, A.
    Akshintala, V.
    Talukdar, R.
    Goenka, M. K.
    Kochhar, R.
    Lakhtakia, S.
    Ramchandani, M. K.
    Sinha, S.
    Goud, R.
    Rai, V. K.
    Vijay, K.
    Elmunzer, B. J.
    Khashab, M.
    Kalloo, A.
    Reddy, N.
    Singh, V. K.
    PANCREAS, 2017, 46 (10) : 1409 - 1409
  • [28] A Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin Alone for the Prevention of Post-Ercp Pancreatitis in High Risk Patients
    Kamal, Ayesha
    Akshintala, Venkata S.
    Talukdar, Rupjyoti
    Goenka, Mahesh K.
    Kochhar, Rakesh
    Hutfless, Susan M.
    Lakhtakia, Sundeep
    Ramchandani, Mohan K.
    Sinha, Saroj
    Goud, Rajesh
    Rai, Vijay K.
    Tandan, Manu
    Gupta, Rajesh
    Ngamruengphong, Saowonee
    Kumbhari, Vivek
    Khashab, Mouen A.
    Elmunzer, Badih Joseph
    Kalloo, Anthony N.
    Reddy, Duvur N.
    Singh, Vikesh
    GASTROINTESTINAL ENDOSCOPY, 2017, 85 (05) : AB78 - AB79
  • [29] Prophylactic Rectal Indomethacin and Prophylactic Pancreatic Duct Stents (PPS) for Prevention of Post-ERCP Pancreatitis Are Underutilized in Average and High-Risk Patients Undergoing ERCP
    Issak, Abdulfatah
    Elangovan, Abbinaya
    Ferguson, Roy
    Waghray, Nisheet
    Sandhu, Dalbir S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S39 - S39
  • [30] Nafamostat Mesilate in the Prevention of Post-ERCP Pancreatitis and Risk Factors for Post-ERCP Pancreattis
    Choi, Cheol Woong
    Kang, Dae Hwan
    Kim, Hyung Wook
    Park, Chan Ho
    Bae, Yong Mock
    Lee, Sang-Yong
    Park, Hyoung-Yoel
    Kim, Yong Wuk
    Lee, Jae Seung
    Kim, Jeong Yeol
    Heo, Jeung Ho
    Jeong, Eul Jo
    GASTROINTESTINAL ENDOSCOPY, 2009, 69 (05) : AB269 - AB269